Cutting-Edge Myopia and Dry Eye Treatment Technologies for Your Practice in 2024
Clinicians across the United States are encountering patients like Emma, a nine-year-old whose myopia progressed by -1.50 diopters in just eighteen months. Her parents arrived desperate for options beyond stronger glasses every year. Meanwhile, Mark, a software engineer in his forties, had tried three different dry eye therapies but still couldn’t complete a workday without burning sensations and blurred vision. These stories repeat daily in practices nationwide—14 million Americans live with myopia, and nearly 16 million suffer from dry eye disease. Both conditions surge year after year, demanding that practitioners integrate advanced diagnostics and therapies into their workflow. For clinicians ready to deliver evidence-based care that addresses root causes and slows progression, exploring comprehensive Myopia and Dry Eye Treatment solutions is the first step toward transforming patient outcomes.
This article synthesizes 2024 clinical data, regulatory updates, and emerging technologies. It provides implementation guidance grounded in real-world workflow, safety protocols, and reimbursement models so your practice can confidently adopt innovations that make a measurable difference.
2024 Technology Snapshot for Myopia and Dry Eye
What’s New and Clinically Relevant Now
The myopia management landscape shifted dramatically in early 2024. SightGlass Vision’s Diffusion Optics Technology spectacle lenses earned FDA Breakthrough Device designation in February, backed by four-year pivotal data showing statistically significant slowing of axial length and cycloplegic spherical equivalent progression. This milestone offers a low-risk, non-surgical option ideal for younger children or families hesitant about contact lenses or pharmaceutical interventions.
Photobiomodulation entered the clinical conversation with the MyopiaX platform by Dopavision. The MyopiaX-1 proof-of-concept trial enrolled 124 children across six European countries and reported six-month safety and tolerability with no ocular safety events. Full trial completion occurred in September 2024. The digital therapeutic uses targeted light via consumer electronics to stimulate retinal pathways—possibly through dopamine-mediated mechanisms—to modulate axial elongation.
Low-level red light therapy continues to generate both excitement and concern. Studies report slowing myopia progression by up to 80 percent in some cohorts, and the treatment is approved in parts of Europe, Australia, and China. However, recent analysis warns that light levels from certain devices may approach or exceed maximum permissible exposure, putting the retina at risk of photochemical and thermal damage. The therapy remains unapproved by the FDA in the United States, and experts urge caution until robust long-term safety data emerges.
On the diagnostic front, researchers from Tokyo Medical and Dental University pioneered polarization-sensitive optical coherence tomography to inspect scleral collagen fiber structure in 89 highly myopic eyes. This imaging provides insights into scleral pathologies like dome-shaped macula and staphylomas, potentially guiding surveillance intervals and timely referral for posterior segment complications.
Fast Facts for Decisions at Chairside
Dry eye disease affects 5 to 20 percent of people in Western nations and a staggering 45 to 70 percent in Asian countries. Despite numerous treatment options—from over-the-counter lubricants to prescription immunomodulators—many patients continue to experience symptoms that limit quality of life. The 2024 focus is on better-tolerated therapeutics and novel drug delivery methods designed to minimize irritation and adverse events, which are common obstacles to adherence and efficacy.
Artificial intelligence is emerging as a powerful tool in dry eye management. A September 2024 narrative review highlights AI’s potential for automated image grading, multimodal data fusion, personalized treatment pathways, and prediction of therapeutic response. However, these technologies require validation, transparency, and bias mitigation before routine clinical integration. Practitioners must build governance for model selection, clinician oversight, and documentation of AI-assisted decisions to ensure ethical and effective use.
Myopia Management Technologies You Can Deploy in 2024
Photobiomodulation for Pediatric Myopia: MyopiaX by Dopavision
The MyopiaX platform delivers photobiomodulation via consumer electronics, targeting specific retinal cells to stimulate innate signaling pathways. The proposed mechanism involves dopamine-mediated regulation of axial elongation, a core driver of myopia progression in children. This non-invasive approach offers an appealing alternative to pharmacologic agents or overnight orthokeratology, particularly for families seeking digital-native solutions.
The MyopiaX-1 randomized controlled trial included 124 children across six European countries and demonstrated six-month safety and tolerability with no ocular safety events. Full trial results became available in September 2024, providing the first glimpse into efficacy endpoints such as axial length and cycloplegic refraction change. While long-term data is still accumulating, early findings suggest the therapy is well-tolerated and warrants consideration in pediatric myopia control protocols where regulatory approval exists.
Integration into clinical workflow requires thoughtful candidate selection. Baseline axial length and cycloplegic refraction establish a reference point. Adherence coaching is critical—families must commit to consistent daily use of the device at home. Outcome tracking every three to six months allows clinicians to assess progression rate and adjust management as needed. This approach works best when paired with comprehensive education about myopia risks and the rationale for early intervention.
Low-Level Red Light Therapy: Promise vs Risk
Low-level red light therapy involves twice-daily three-minute exposures to specific wavelengths of red light. Studies report slowing myopia progression by up to 80 percent in some cohorts, and the treatment has regulatory approval in parts of Europe, Australia, and China. This efficacy profile has captured the attention of clinicians and families eager for non-pharmaceutical options.
However, significant safety concerns have emerged. A recent analysis warned that light levels from some LLRL devices may approach or exceed maximum permissible exposure limits established to protect against photochemical and thermal retinal damage. The therapy is not FDA-approved in the United States, and long-term safety data remains sparse. Clinicians must weigh the reported benefits against the potential for irreversible retinal harm, particularly in pediatric populations whose eyes are still developing.
Counseling patients and families about benefit-risk uncertainty is essential. Practitioners should avoid off-label use of LLRL in the United States until robust safety studies and FDA clearance are available. In regions where the therapy is approved, close monitoring of symptoms, visual acuity, and retinal health is mandatory. Document informed consent thoroughly, clearly outlining the experimental nature of the treatment, the potential for ocular damage, and the availability of safer alternatives with longer safety track records.
Advanced Spectacle Lenses: SightGlass Vision Diffusion Optics Technology
SightGlass Vision’s Diffusion Optics Technology spectacle lenses earned FDA Breakthrough Device designation in February 2024, supported by four-year pivotal data showing statistically significant slowing of axial length and cycloplegic spherical equivalent progression. This regulatory milestone marks a turning point for non-invasive myopia control in the United States, offering a low-risk option that fits seamlessly into existing optical dispensing workflows.
The lenses are ideal for younger children who are not candidates for contact lenses or families who prefer a simple, pharmaceutical-free approach. Implementation is straightforward: streamline fitting procedures, counsel families on adaptation timelines, and schedule six-month axial length checks to track efficacy. The technology does not require overnight wear, complex cleaning protocols, or daily medication, making it an attractive first-line option for many patients.
Enhanced Diagnostics: Polarization-Sensitive OCT for High Myopia
Polarization-sensitive optical coherence tomography represents a leap forward in imaging for highly myopic eyes. Researchers from Tokyo Medical and Dental University used this technology to assess scleral collagen architecture in 89 highly myopic eyes, revealing insights into scleral pathologies such as dome-shaped macula and staphylomas. These structural changes are associated with increased risk of retinal complications, including macular atrophy and choroidal neovascularization.
The clinical impact is clear: this imaging modality guides surveillance intervals and informs decisions about referral for posterior segment complications. Practitioners managing high myopia patients can use polarization-sensitive OCT to stratify risk, personalize monitoring cadence, and intervene earlier when pathologic changes are detected. As the technology becomes more widely available, it has the potential to become a standard component of comprehensive myopia management protocols.
Positioning with Established Options
The expanding toolkit for myopia control creates both opportunity and complexity. Clinicians must combine or sequence new technologies with established options such as atropine, orthokeratology, and multifocal soft lenses based on patient age, progression rate, refractive error, and lifestyle. Prioritize modalities with the strongest safety and regulatory clarity first. For example, start with FDA-designated spectacle lenses or low-dose atropine, then consider photobiomodulation or orthokeratology in cases of rapid progression or specific patient preferences. Avoid LLRL in the United States until safety data and regulatory approval are secured. This evidence-weighted approach protects patients while delivering measurable outcomes.
Dry Eye Disease Innovations: Better Tolerability and Personalization
Prevalence and Unmet Needs to Address in Clinic
Dry eye disease affects 5 to 20 percent of people in Western nations and 45 to 70 percent in Asian countries. This staggering prevalence underscores the scale of the problem facing practitioners. Despite a broad array of therapies—from artificial tears to cyclosporine and lifitegrast—many patients report persistent symptoms that interfere with work, reading, driving, and other daily activities. Adherence and tolerability gaps remain major obstacles. Patients abandon treatments that cause stinging, blurred vision, or other adverse effects, leaving them without effective relief. The challenge for 2024 is to close this gap by prioritizing therapies that target disease mechanisms while minimizing discomfort.
Novel Drug Delivery and Better-Tolerated Therapeutics
A 2024 review highlights a shift beyond symptom relief toward targeting the underlying causes of dry eye disease. Novel drug delivery methods are designed to minimize irritation and adverse events that plague traditional formulations. These innovations include sustained-release inserts, lipid-based emulsions, and advanced polymers that enhance bioavailability while reducing preservative exposure. The goal is to deliver therapeutic molecules to the ocular surface with fewer application cycles and less discomfort.
Clinical takeaways are straightforward: match delivery innovations to phenotype. For evaporative dry eye driven by meibomian gland dysfunction, consider lipid-based emulsions or in-office thermal pulsation. For aqueous-deficient disease, sustained-release inserts may provide consistent lubrication without frequent dosing. Emphasize tolerability-first trials and implement stepwise trials of therapy with objective metrics such as tear breakup time, osmolarity, and corneal staining alongside patient-reported outcome measures like the Ocular Surface Disease Index. This dual approach ensures that treatment decisions are grounded in both biological evidence and patient experience.
AI in Dry Eye Disease: Diagnostics, Personalization, and Prediction
Artificial intelligence is poised to transform dry eye management through automated image grading, multimodal data fusion, personalized treatment pathways, and prediction of therapeutic response. A September 2024 narrative review outlines these capabilities while emphasizing the need for validation, transparency, and bias mitigation. AI algorithms trained on diverse datasets can identify subtle meibomian gland atrophy, grade lipid layer thickness from interferometry images, and integrate questionnaire data to recommend individualized therapies.
However, caveats are essential. These tools require rigorous clinical validation before routine use. Practitioners must ensure transparency in how algorithms reach their conclusions and mitigate bias that could lead to disparities in care. Build governance frameworks for model selection, maintain clinician oversight of AI-assisted decisions, and document the rationale for each treatment recommendation. AI should augment, not replace, clinical judgment, and patients must be informed when algorithms contribute to their care plan.
Integrating with In-Office Modalities and Diagnostics
Pair AI-ready imaging—such as meibography, anterior segment photography, and tear film interferometry—with osmolarity testing and validated questionnaires to create a comprehensive dry eye assessment. Integrate these data streams with existing in-office modalities, including thermal pulsation devices, intense pulsed light therapy, and meibomian gland expression techniques. The result is a refined selection process that matches patients to the therapies most likely to succeed while reducing trial-and-error cycles. This approach improves outcomes, enhances patient satisfaction, and builds a reputation for delivering cutting-edge, evidence-based care.
Implementation Playbook for Your Practice
Workflow and Staffing
Designate a myopia and dry eye lead within your practice to champion new technologies, coordinate training, and ensure consistent protocols. Create standardized intake forms that capture axial length, cycloplegic refraction, and Ocular Surface Disease Index scores at baseline. Train technicians on device operation, imaging acquisition, and adherence coaching so every patient receives uniform care regardless of which staff member they encounter. This structure reduces variability, improves data quality, and frees clinicians to focus on interpretation and decision-making.
Safety Protocols, Informed Consent, and Documentation
Clearly disclose the regulatory status of each technology. For example, low-level red light therapy is not FDA-approved in the United States, while SightGlass Vision lenses have Breakthrough Device designation. Outline potential risks, including rare but serious adverse events, and present alternatives. Define stopping rules—specific criteria that trigger discontinuation or escalation of care. Record baseline and follow-up metrics consistently in the electronic health record so you can track trends, identify non-responders, and adjust protocols as new evidence emerges. Thorough documentation protects both patients and practitioners while supporting quality improvement initiatives.
Patient Education and Adherence Tools
Provide concise handouts that explain the rationale for each therapy, expected timelines for improvement, and monitoring schedules. Use app-based reminders for home-based therapies such as photobiomodulation or twice-daily red light sessions in approved regions. Set clear expectations: myopia control takes months to years to demonstrate slowing, and dry eye therapies may require eight to twelve weeks before significant symptom relief occurs. Patients who understand the science and timeline are more likely to adhere, resulting in better outcomes and fewer frustrations.
Regulatory and Risk Management Essentials
FDA Status by Technology
SightGlass Vision Diffusion Optics Technology spectacle lenses hold FDA Breakthrough Device designation, signaling a pathway to approval based on compelling efficacy data. Low-level red light therapy remains unapproved by the FDA in the United States, and practitioners should not offer it outside of approved research protocols. Digital photobiomodulation by MyopiaX is investigational, with early safety data from European trials now available. Verify the current regulatory status of each technology before integrating it into your practice, and communicate this information transparently to patients. Regulatory landscapes evolve rapidly, and staying informed protects your practice from liability while ensuring patients receive only evidence-based care.
Data Ethics and Privacy for AI and Digital Therapeutics
Ensure that all data flows comply with the Health Insurance Portability and Accountability Act. Obtain explicit consent from patients before using AI-assisted care tools, and explain how their data will be used, stored, and protected. Address bias by selecting algorithms trained on diverse populations and validating performance across demographic groups. Maintain explainability—patients and clinicians should understand how AI reaches its conclusions. Document clinician oversight in every AI-assisted decision, reinforcing that the final treatment plan rests with the practitioner, not the algorithm. These safeguards build trust, mitigate risk, and ensure ethical use of emerging technologies.
Reimbursement and Business Model Options
Coding and Self-Pay Strategies
Use appropriate diagnostic and management codes where eligible to capture reimbursement for myopia control and dry eye management. Many advanced therapies, however, are not covered by insurance. Package non-covered services—such as myopia control programs or comprehensive dry eye care—with transparent pricing and financing options. Offer monthly payment plans, bundled visit packages, and clear itemized invoices so families can budget for care without surprise costs. This approach aligns patient expectations with practice economics while maintaining access to innovative therapies.
ROI Drivers and Pricing Considerations
Model device utilization, staff time, follow-up cadence, and patient retention to estimate revenue per enrolled patient. Track outcomes rigorously and reinvest in technology upgrades, training, and marketing that highlight your expertise in advanced myopia and dry eye management. Practices that can demonstrate slowed axial elongation or improved dry eye metrics attract referrals, build loyalty, and command premium pricing. Calculate return on investment over multi-year horizons, recognizing that some technologies require upfront capital and training but deliver sustained revenue streams as patient volumes grow.
Evidence-Weighted Clinical Algorithms
Pediatric Myopia Control Pathway
Assess baseline risk and progression rate using cycloplegic refraction and axial length measurement. Start with spectacle lenses or low-dose atropine as first-line options given their safety profiles and regulatory clarity. Consider photobiomodulation in regions where it is available and validated, particularly for families seeking digital-native solutions. Avoid low-level red light therapy in the United States until FDA approval and long-term safety data are available. Monitor axial length and refraction every six months. If progression persists despite initial intervention, escalate to combination therapy or orthokeratology. This algorithm prioritizes safety, evidence, and patient preference while maintaining flexibility to adapt as new data emerges.
Dry Eye Treatment Pathway Emphasizing Tolerability
Phenotype the patient using meibography, tear breakup time, osmolarity, and corneal staining. Optimize environmental factors and reinforce lid hygiene as foundational steps. Select therapies with better-tolerated delivery methods—sustained-release inserts for aqueous deficiency, lipid-based emulsions for evaporative disease. Personalize treatment pathways using AI insights as they become validated and available. Reassess Ocular Surface Disease Index, tear breakup time, and staining at eight to twelve weeks. If symptoms persist or adverse events occur, iterate to alternative mechanisms or delivery systems. This pathway minimizes discomfort, maximizes adherence, and delivers meaningful symptom relief while addressing underlying pathophysiology.
Outcomes Tracking and Quality Improvement
KPIs and Measurement Cadence
For myopia management, track axial length change, cycloplegic spherical equivalent refraction, and patient adherence at six-month intervals. For dry eye disease, monitor Ocular Surface Disease Index scores, tear film stability, corneal and conjunctival staining, meibography grading, and patient-reported comfort at baseline and every eight to twelve weeks. These key performance indicators allow you to identify non-responders, adjust protocols, and demonstrate efficacy to patients and referring providers. Regular measurement also supports quality improvement initiatives and practice marketing by providing concrete evidence of your clinical impact.
Leveraging EHR, Registries, and AI Dashboards
Build structured templates in your electronic health record to capture baseline and follow-up metrics consistently. Anonymize data and contribute to myopia or dry eye registries to benchmark your outcomes against national or international cohorts. Use AI dashboards to visualize trends, spot outliers, and optimize care pathways. For example, a dashboard might reveal that patients with specific meibomian gland atrophy patterns respond better to thermal pulsation than to pharmaceutical therapy, prompting protocol adjustments. These tools transform raw data into actionable intelligence, driving continuous improvement and positioning your practice as a leader in evidence-based eye care.
The technologies available in 2024 offer unprecedented opportunities to slow myopia progression and deliver lasting dry eye relief. By integrating advanced diagnostics, evidence-weighted therapies, rigorous safety protocols, and robust outcomes tracking, your practice can meet the needs of patients like Emma and Mark—transforming their lives while building a reputation for clinical excellence and innovation.

